The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Tags · Access

compounding

Pharmacy preparation of a formulation not commercially available.

54 topics 14 solved Synonyms: 503a, 503b Group: Access

Related in this group: insurance · prior authorisation · appeals · formulary · cost per milligram · shortage · NHS · EMA · FDA · MHRA · personal import · telehealth

54 topics · page 1 of 2

TopicParticipantsRepliesViewsActivity
Why the cheapest option is often not the cheapest
Why the cheapest option is often not the cheapest I have a specific reason for asking rather than idle curiosity, and the context is below. Cheapest option: setting out the arithmetic in full, because I have…
ZIVOTMA+19 23 1.2k 12h
What a regulator's shortage notice actually authorises
What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked. Asking what a regulator's document actually says, since the…
BESCAAQLSG+8 12 15k 17h
How shortages have affected compounding permissions — does this still hold?
How shortages have affected compounding permissions — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Asking about shortages directly, because I…
BVYRVKSSAS+27 31 21k 17h
Coming back to: Telehealth prescribing models in the US
Posting this under the heading it deserves: Telehealth prescribing models in the US Everything below is what sits behind that. Telehealth prescribing models — I have the observation and I do not trust my…
LCNBHFTIEM+26 30 17k 17h
[2026 update] Comparing prices across jurisdictions without misleading yourself
On the subject in the title: Comparing prices across jurisdictions without misleading yourself Working notes rather than a conclusion. Comparing prices across jurisdictions keeps being re-asked here and I…
SDICP 2 809 23h
Tracking a shortage from primary sources rather than rumour — the long version
On the subject in the title: Tracking a shortage from primary sources rather than rumour — the long version Working notes rather than a conclusion. Tracking a shortage keeps being re-asked here and I think…
SDLSNM 2 60 1d
About the Shortages category
Supply interruptions, official shortage notices, and managing an unplanned gap. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and…
JMTVMMGVTW+3 7 9.9k 1d
How shortages have affected compounding permissions
How shortages have affected compounding permissions I have a specific reason for asking rather than idle curiosity, and the context is below. I would like to know what people here actually do about shortages,…
CRLMCKTFGT+61 71 3.6k 2d
Substitution between formats during a shortage — what changed since
Substitution between formats during a shortage — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Substitution between formats…
SBKACONKWN+17 21 2.7k 9d
Manufacturer assistance programmes and their eligibility rules
On the subject in the title: Manufacturer assistance programmes and their eligibility rules Working notes rather than a conclusion. I have spent a fortnight trying to pin manufacturer assistance programmes…
TPHFRMIBCR+37 42 32k 11d
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. Posting a small dataset on Prescription requirements and telehealth…
MOLAPFPHB+87 94 1.1k 21d
Official shortage notices and what they authorise
Posting this under the heading it deserves: Official shortage notices and what they authorise Everything below is what sits behind that. Trying to work out what would count as evidence on official shortage…
AVPPNSNGRM+106 119 18k 1mo
Comparing prices across jurisdictions without misleading yourself
Comparing prices across jurisdictions without misleading yourself — setting out what I have, and where I think it stops being reliable. Working notes on comparing prices across jurisdictions rather than a…
LCGFVTPOO+78 83 33k 1mo
Labelling requirements for research chemicals — the long version
Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that. A narrow question about Labelling requirements for…
LSDBHK 2 1.8k 2mo
Managing an unplanned gap in supply
Managing an unplanned gap in supply — setting out what I have, and where I think it stops being reliable. A narrow question about managing an unplanned gap, deliberately narrow, because the broad version has…
LSFPASLCVK+105 110 5.1k 3mo
Price changes over 2025 and 2026, tabulated and dated — does this still hold?
Price changes over 2025 and 2026, tabulated and dated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated,…
WMCCDFKSDO+147 156 18k 3mo
Why a compound being unapproved is not the same as being illegal to possess
Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Collecting what is known about compound…
LCFNJBSCAN+72 78 23k 3mo
List price versus negotiated price versus what you pay
On the subject in the title: List price versus negotiated price versus what you pay Working notes rather than a conclusion. List price versus negotiated price — I have the observation and I do not trust my…
JPJAVFVBCA+99 115 11k 3mo
About the Regulatory category
Research-use-only status, compounding rules, import restrictions, and the primary documents behind them. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
OBSLKEFNV 4 49k 4mo
Cost per delivered dose, which is the number that matters
Cost per delivered dose, which is the number that matters — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in this category…
MYFTATRFAD+54 59 30k 4mo
Reading a regulatory notice rather than an article about it
Posting this under the heading it deserves: Reading a regulatory notice rather than an article about it Everything below is what sits behind that. Posting a small dataset on reading a regulatory notice. It is…
COKRSI 2 2.9k 5mo
Research-use-only labelling: what it means and what it does not
Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. A labelling question, and I would like the answer to be…
ZNPPJENGGR+100 110 37k 5mo
Coverage in the US: a map of the usual obstacles
Coverage in the US: a map of the usual obstacles — setting out what I have, and where I think it stops being reliable. Trying to establish the boundary conditions on coverage. The general claim is fine; I…
GPMYASKHFA+46 50 7.9k 5mo
Prescription requirements and telehealth models
Prescription requirements and telehealth models Writing it up because I had to work it out twice and would rather nobody else did. Proposing that prescription requirements and telehealth models deserves a…
MBNHKDWV+91 97 5.4k 7mo
What a regulator's shortage notice actually authorises — what changed since
The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it. Asking what a regulator's document…
JMMBUCRVW+22 26 53k 7mo
Substitution between formats during a shortage
On the subject in the title: Substitution between formats during a shortage Working notes rather than a conclusion. The question about substitution between formats that I actually want answered is the second…
PATBDAMCW+114 123 47k 7mo
Pharmaceutical compounding rules, summarised from primary sources — a second dataset
Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind that. Asking what a regulator's document…
CRDPICCDJB+50 56 780 8mo
Managing an unplanned gap in supply — what changed since
On the subject in the title: Managing an unplanned gap in supply — what changed since Working notes rather than a conclusion. What changes if the standard account of Managing an unplanned gap is wrong? I ask…
FEELIGRAC+114 124 54k 8mo
Second pass at: Coverage in the US: a map of the usual obstacles
On the subject in the title: Second pass at: Coverage in the US: a map of the usual obstacles Working notes rather than a conclusion. Two things I would like separated before anyone answers on Coverage,…
SAEDERSGAK 4 62k 9mo
About the North America category
US and Canadian regulation, compounding, and coverage. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a note. If the scope…
KTVEKCNB+3 7 43k 9mo